All News

obesity.back_.jpg

The Power of Self-Management with Chronic Low Back Pain

EurekAlert!

Almost everyone will deal with back pain at some point in their lives.

Read Article
Canada.maple.leaf

ICYMI: Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis

Jack Cush, MD

In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial spondyloarthritis. This first update is focused on the reassessment of IL-17i recommendations.

Read Article
ILD damage fibrosis path

EULAR26: ANCHOR-RA Study of RA-ILD

EurekAlert!

People with rheumatoid arthritis are at risk of developing interstitial lung disease (RA-ILD), which is associated with high mortality.

Read Article
Giant-Cell_Vasculitis.jpg

EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA

EurekAlert!

EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.

Read Article
uricacid.jpg

ICYMI: Worldwide Trends in Hyperuricemia

Jack Cush, MD

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

Read Article
GLP-1.pink

EULAR26: GLP-1 Agonist Use in the RISE Registry

EurekAlert!

At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). 

Read Article
Vexas

ICYMI: VEXAS Syndrome - A Review

Jack Cush, MD

Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.

Read Article
Knee,injection

ICYMI: Glucocorticoid Injections in Knee Osteoarthritis

Jack Cush, MD

A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).

Read Article
ICYMI: Worldwide Trends in Hyperuricemia A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates. https://t.co/8QAWkka0DM
Dr. John Cush RheumNow ( View Tweet)
2026 Guidelines for the Treatment of Axial Spondyloarthritis New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/3V8bfDptDU
Dr. John Cush RheumNow ( View Tweet)
EULAR26: GLP-1 Agonist Use in the RISE Registry At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). https://t.co/EqgETKjN1v
Dr. John Cush RheumNow ( View Tweet)
RheumIQ: True or False: In the NORD-STAR trial, failure to achieve early remission in RA was associated with a significantly increased risk of fibromyalgic RA at 48 weeks. Find out if you got it right at https://t.co/z8mLbcgE5D. https://t.co/vkusOYHcQj

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @aurelierheumo What is new in PsA? Dennis McGonagle's take at #EULAR2026 -a strong year for discovery in mechanisms of transition from PSO to PsA -publication of the first single cell atlas Enthesis -Better understanding of VTE mechanisms in JAKi in PsA -clinical aspects

Dr. John Cush RheumNow ( View Tweet)

RT @jiharheum MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. #EULAR2026 OP0206

Dr. John Cush RheumNow ( View Tweet)

NEW FROM EULAR: A real-world analysis of predictors of IBD in PsA. 🔎 In patients with PsA, signs and symptoms of IBD may appear before diagnosis, but do we know what to look for? Explore the poster: https://t.co/x2pM0T9LWg Sponsored by AbbVie Medical Affairs + Health Impact.

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Glucocorticoid Injections in Knee Osteoarthritis A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to https://t.co/QhW7CMx72x
Dr. John Cush RheumNow ( View Tweet)
ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management EULAR has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous https://t.co/6WAZB1dOpI
Dr. John Cush RheumNow ( View Tweet)
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026

Dr. John Cush RheumNow ( View Tweet)

RT @aurelierheumo Failure to achieve early remission RA asso w/ non-inflammatory pain NORD-STAR 526 early RA pts) no remission at 24 wks increased risk of 48wk • unacceptable pain (OR ~6) • refractory pain (OR ~6) • fibromyalgic RA (OR ~16) Signal strongest w/ very early

Dr. John Cush RheumNow ( View Tweet)

Obexelimab in IgG4-Related Disease: INDIGO Trial Dr. Henrique Dalmolin reports on abstract OP018 from EULAR 2026. https://t.co/Wid9ZzESae https://t.co/Qo4y8ebkOn

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×